28 related articles for article (PubMed ID: 15170662)
1. Inhibitory effect of oversulfated fucoidan on invasion through reconstituted basement membrane by murine Lewis lung carcinoma.
Soeda S; Ishida S; Shimeno H; Nagamatsu A
Jpn J Cancer Res; 1994 Nov; 85(11):1144-50. PubMed ID: 7829400
[TBL] [Abstract][Full Text] [Related]
2. Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.
Asumda FZ; Campbell NA; Hassan MA; Fathi R; Vasquez Rico DF; Kiem M; Vang EV; Kim YH; Luo X; O'Brien DR; Buhrow SA; Reid JM; Moore MJ; Ben-Yair VK; Levitt ML; Leiting JL; Abdelrahman AM; Zhu X; Lucien F; Truty MJ; Roberts LR
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473407
[TBL] [Abstract][Full Text] [Related]
3. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Setyono-Han B; Stürzebecher J; Schmalix WA; Muehlenweg B; Sieuwerts AM; Timmermans M; Magdolen V; Schmitt M; Klijn JG; Foekens JA
Thromb Haemost; 2005 Apr; 93(4):779-86. PubMed ID: 15841327
[TBL] [Abstract][Full Text] [Related]
4. Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.
Zengel P; Ramp D; Mack B; Zahler S; Berghaus A; Muehlenweg B; Gires O; Schmitz S
BMC Cancer; 2010 Mar; 10():92. PubMed ID: 20222943
[TBL] [Abstract][Full Text] [Related]
5. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynolds LM
J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
[TBL] [Abstract][Full Text] [Related]
6. Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynold LM
Adv Exp Med Biol; 1999; 462():399-412. PubMed ID: 10599442
[TBL] [Abstract][Full Text] [Related]
7. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.
Ertongur S; Lang S; Mack B; Wosikowski K; Muehlenweg B; Gires O
Int J Cancer; 2004 Jul; 110(6):815-24. PubMed ID: 15170662
[TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Fazioli F; Blasi F
Trends Pharmacol Sci; 1994 Jan; 15(1):25-9. PubMed ID: 8140655
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
